Pre-IPO bout to value PharmEasy at $6 billion

PharmEasy is finalising a $200-million primary funding round ahead of its initial public offer (IPO) and is in talks with marquee investors from the US and South East Asia, such as Blackstone, BlackRock, Amansa Capital, Janchor Partners and OrbiMed, multiple people in the know told ET.

Simultaneously, the country’s largest e-pharmacy is also stitching up a secondary transaction of up to $100 million, buoyed by high interest from pre-IPO investors looking to come on board, sources said. PharmEasy is likely to be valued at around $6 billion post the funding round, creating a benchmark valuation ahead of a public listing. It was last valued at $4.2 billion in June.